Your browser doesn't support javascript.
loading
Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial report.
Conway, Charles R; Aaronson, Scott T; Sackeim, Harold A; Duffy, Walter; Stedman, Mary; Quevedo, João; Allen, Rebecca M; Riva-Posse, Patricio; Berger, Matthew A; Alva, Gustavo; Malik, Mohd Azfar; Dunner, David L; Cichowicz, Ivan; Luing, Heather; Zajecka, John; Nahas, Ziad; Mickey, Brian J; Kablinger, Anita S; Kriedt, Christopher L; Bunker, Mark T; Lee, Ying-Chieh Lisa; Shy, Olivia; Majewski, Shannon; Olin, Bryan; Tran, Quyen; Rush, A John.
Afiliação
  • Conway CR; Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA. Electronic address: conwaycr@wustl.edu.
  • Aaronson ST; Department of Clinical Research, Sheppard Pratt Health System, Baltimore, MD, USA.
  • Sackeim HA; Departments of Psychiatry and Radiology, Columbia University, New York, NY, USA.
  • Duffy W; Alivation Research, Lincoln, NE, USA.
  • Stedman M; Stedman Clinical Trials, Tampa, FL, USA.
  • Quevedo J; Center for Interventional Psychiatry, Faillace Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston), Houston, TX, USA.
  • Allen RM; Seattle Neuropsychiatric Treatment Center, Seattle, WA, USA.
  • Riva-Posse P; Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.
  • Berger MA; Scranton Medical Institutes, Moosic, PA, USA.
  • Alva G; ATP Clinical Research, Senior Brain Health, Hoag Hospital, Newport Beach, CA and Department of Psychiatry and Neuroscience, University of California, Riverside, CA, USA.
  • Malik MA; PsychCare Consultants Research, St. Louis, MO, USA.
  • Dunner DL; Center for Anxiety and Depression, Mercer Island, WA, USA.
  • Cichowicz I; Mindful Behavioral Health, Boca Raton, FL, USA.
  • Luing H; Florida Center for TMS, St. Augustine, FL, USA.
  • Zajecka J; Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, IL, USA; Psychiatric Medicine Associates, LLC, Skokie, IL, USA.
  • Nahas Z; Department of Psychiatry & Behavioral Sciences, University of Minnesota, Minneapolis, MN, USA.
  • Mickey BJ; Department of Psychiatry, Huntsman Mental Health Institute, University of Utah, Salt Lake City, UT, USA.
  • Kablinger AS; Department of Psychiatry and Behavioral Medicine, Virginia Tech Carilion School of Medicine, Roanoke, VA, USA.
  • Kriedt CL; Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA.
  • Bunker MT; LivaNova PLC (or a Subsidiary), London, Great Britain, United Kingdom.
  • Lee YL; LivaNova PLC (or a Subsidiary), London, Great Britain, United Kingdom.
  • Shy O; LivaNova PLC (or a Subsidiary), London, Great Britain, United Kingdom.
  • Majewski S; LivaNova PLC (or a Subsidiary), London, Great Britain, United Kingdom.
  • Olin B; LivaNova PLC (or a Subsidiary), London, Great Britain, United Kingdom.
  • Tran Q; LivaNova PLC (or a Subsidiary), London, Great Britain, United Kingdom.
  • Rush AJ; Duke-NUS Medical School, Singapore; Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA.
Brain Stimul ; 17(2): 448-459, 2024.
Article em En | MEDLINE | ID: mdl-38574853
ABSTRACT

BACKGROUND:

RECOVER is a randomized sham-controlled trial of vagus nerve stimulation and the largest such trial conducted with a psychiatric neuromodulation intervention.

OBJECTIVE:

To describe pre-implantation baseline clinical characteristics and treatment history of patients with unipolar, major depressive disorder (MDD), overall and as a function of exposure to interventional psychiatric treatments (INTs), including electroconvulsive therapy, transcranial magnetic stimulation, and esketamine.

METHODS:

Medical, psychiatric, and treatment records were reviewed by study investigators and an independent Study Eligibility Committee prior to study qualification. Clinical characteristics and treatment history (using Antidepressant Treatment History [Short] Form) were compared in those qualified (N = 493) versus not qualified (N = 228) for RECOVER, and among the qualified group as a function of exposure to INTs during the current major depressive episode (MDE).

RESULTS:

Unipolar MDD patients who qualified for RECOVER had marked TRD (median of 11.0 lifetime failed antidepressant treatments), severe disability (median WHODAS score of 50.0), and high rate of baseline suicidality (77% suicidal ideation, 40% previous suicide attempts). Overall, 71% had received at least one INT. Compared to the no INT group, INT recipients were younger and more severely depressed (QIDS-C, QIDS-SR), had greater suicidal ideation, earlier diagnosis of MDD, and failed more antidepressant medication trials.

CONCLUSIONS:

RECOVER-qualified unipolar patients had marked TRD and marked treatment resistance with most failing one or more prior INTs. Treatment with ≥1 INTs in the current MDE was associated with earlier age of MDD onset, more severe clinical presentation, and greater treatment resistance relative to patients without a history of INT. TRIAL REGISTRATION ClinicalTrials.gov Identifier NCT03887715.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtorno Depressivo Maior / Estimulação Magnética Transcraniana / Transtorno Depressivo Resistente a Tratamento Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transtorno Depressivo Maior / Estimulação Magnética Transcraniana / Transtorno Depressivo Resistente a Tratamento Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article